Chinese Chemical Letters, Journal Year: 2025, Volume and Issue: unknown, P. 110991 - 110991
Published: Feb. 1, 2025
Language: Английский
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Nov. 28, 2023
The advent of iPSCs has brought about a significant transformation in stem cell research, opening up promising avenues for advancing cancer treatment. formation is multifaceted process influenced by genetic, epigenetic, and environmental factors. offer distinctive platform investigating the origin cancer, paving way novel approaches to treatment, drug testing, tailored medical interventions. This review article will provide an overview science behind iPSCs, current limitations challenges iPSC-based therapy, ethical social implications, comparative analysis with other types also discuss applications tumorigenesis, future tumorigenesis highlight successful case studies utilizing research. conclusion summarize advancements made research importance continued investment iPSC unlock full potential these cells.
Language: Английский
Citations
73
Nature Reviews Clinical Oncology, Journal Year: 2024, Volume and Issue: 21(7), P. 539 - 560
Published: May 31, 2024
Language: Английский
Citations
37
Cancers, Journal Year: 2024, Volume and Issue: 16(3), P. 552 - 552
Published: Jan. 27, 2024
The hormone receptor-positive (HR+) type is the most frequently identified subtype of breast cancer. HR+ cancer has a more positive prognosis when compared to other subtypes, such as human epidermal growth factor protein 2-positive disorder and triple-negative disease. advancement in treatment outcomes for advanced been considerably elevated due discovery cyclin-dependent kinase 4/6 inhibitors their combination effects with endocrine therapy. However, despite considerable effectiveness tamoxifen, selective estrogen receptor modulator (SERMs), aromatase (AI), issue resistance still presents significant challenge As result, there focus on exploring new therapeutic strategies targeted degradation covalent inhibition targeting ERα. This article discusses latest progress treatments like oral ER degraders (SERDs), complete antagonists (CERANs), (SERCAs), proteolysis chimera (PROTAC) degraders, combinations CDK4/6 specifically those compounds that have transitioned into phases clinical development.
Language: Английский
Citations
20
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(2), P. 1064 - 1064
Published: Jan. 15, 2024
Human epidermal growth factor receptor 2 (HER2) belongs to the ErbB family, a group of four transmembrane glycoproteins with tyrosine kinase activity, all structurally related (EGFR). These kinases are involved in transmission cellular signals controlling normal cell and differentiation. If this goes awry, it can lead dysregulated cell. HER2 specifically be implicated pathogenesis at least eight malignancies. positivity quickly became well-characterized indicator aggressiveness poor prognosis, high rates disease progression mortality. After realizing implication HER2, first investigated as target for treatment breast cancer, later expanded areas research other cancer types. To day, most therapeutic advancements anti-HER2 therapy have been cancer; however, there strong made incorporation types well. This comprehensive review dissects its core, incorporating up date information. The topics touched upon discussed detail 200 published sources from highly recognized journals integrated. importance knowing about is exemplified by groundbreaking that made, change plans has brought oncological world last twenty years. Since discovery significant breakthroughs knowledge regarding actual receptor, receptors biology, mechanism action, tests detect strides on how best incorporate targeted treatment. Due success field thus far, concludes discussing future novel currently development everyone should aware of.
Language: Английский
Citations
19
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Nov. 8, 2024
Immunotherapy has ushered in a new era of cancer treatment, yet remains leading cause global mortality. Among various therapeutic strategies, vaccines have shown promise by activating the immune system to specifically target cells. While current are primarily prophylactic, advancements targeting tumor-associated antigens (TAAs) and neoantigens paved way for vaccines. The integration artificial intelligence (AI) into vaccine development is revolutionizing field enhancing aspect design delivery. This review explores how AI facilitates precise epitope design, optimizes mRNA DNA instructions, enables personalized strategies predicting patient responses. By utilizing technologies, researchers can navigate complex biological datasets uncover novel targets, thereby improving precision efficacy Despite AI-powered vaccines, significant challenges remain, such as tumor heterogeneity genetic variability, which limit effectiveness neoantigen prediction. Moreover, ethical regulatory concerns surrounding data privacy algorithmic bias must be addressed ensure responsible deployment. future lies seamless create immunotherapies that offer targeted effective treatments. underscores importance interdisciplinary collaboration innovation overcoming these advancing development.
Language: Английский
Citations
14
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(3), P. 1941 - 1941
Published: Feb. 5, 2024
Monoclonal antibody (mAb)-based and/or cell-based immunotherapies provide innovative approaches to cancer treatments. However, safety concerns over targeting normal cells expressing reactive antigens still exist. Therefore, the development of cancer-specific mAbs (CasMabs) that recognize with in vivo antitumor efficacy is required minimize adverse effects. We previously screened anti-human epidermal growth factor receptor 2 (HER2) and successfully established a anti-HER2 mAb, H
Language: Английский
Citations
12
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Journal Year: 2024, Volume and Issue: 43(2), P. 35 - 43
Published: April 1, 2024
Overexpression of human epidermal growth factor receptor 2 (HER2) in breast and gastric cancers is an important target for monoclonal antibody (mAb) therapy. All therapeutic mAbs, including anti-HER2 exhibit adverse effects probably due to the recognition antigens expressed normal cells. Therefore, tumor-selective or specific mAbs can be beneficial reducing effects. In this study, we established a novel cancer-specific antibody, named H
Language: Английский
Citations
11
Analytical Chemistry, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 9, 2025
Accurate identification of cancer cells under complex physiological environments holds great promise for noninvasive diagnosis and personalized medicine. Herein, we developed dual-aptamer-based DNA logic-gated series lamp probes (DApt-SLP) by coupling a cell-classifier (DCC) with self-powered signal-amplifier (SSA), enabling rapid sensitive in blood sample. DCC is endowed two extended-aptamer based modules recognizing the cascade cell membrane receptors serves as logic gate to pinpoint particular narrow subpopulation from larger population similar cells. leverages dual-receptor co-recognition strategy enhanced specificity performing matching operation between aptamer receptor twice on membranes. SSA signal converter attached at end that changes process into detectable signals, well amplifier output amplified signals using simple efficient hybridization chain reaction. Unique those who are multicomponent systems, DApt-SLP an all-in-one compact nanodevice, exhibiting nuclease-degradation resistance targeting ability. In vitro feasibility, imaging, flow cytometry analysis showed system successfully operated buffered solution environment precisely differentiated target large populations Benefiting its integrated design single-step high sensitivity accuracy, practical tool medicine biomedical engineering.
Language: Английский
Citations
1
Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 8, 2025
Metabolic reprogramming within the tumor microenvironment (TME) plays a critical role in driving drug resistance gastrointestinal cancers (GI), particularly through pathways of fatty acid oxidation and glycolysis. Cancer cells often rewire their metabolism to sustain growth reshape TME, creating conditions such as nutrient depletion, hypoxia, acidity that impair antitumor immune responses. Immune TME also undergo metabolic alterations, frequently adopting immunosuppressive phenotypes promote progression reduce efficacy therapies. The competition for essential nutrients, glucose, between cancer compromises functions effector cells, T cells. Additionally, by-products like lactate kynurenine further suppress activity populations, including regulatory M2 macrophages. Targeting glycolysis presents new opportunities overcome improve therapeutic outcomes GI cancers. Modulating these key has potential reinvigorate exhausted shift toward phenotypes, enhance effectiveness immunotherapies other treatments. Future strategies will require continued research into metabolism, development novel inhibitors, clinical trials evaluating combination Identifying validating biomarkers be crucial patient stratification treatment monitoring. Insights may have broader implications across multiple types, offering avenues improving treatment.
Language: Английский
Citations
1
Cancer Pathogenesis and Therapy, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
1